IO Biotech, Inc.
IOBTDelisted Jun 8, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001865494
IO Biotech, Inc. was delisted on Jun 8, 2026; its insiders filed their last Form 4 on Jun 6, 2025; 12 institutions reported holding it in 13F filings for Q1 2026, worth $199.0K in total; no superinvestor held it.
13F holders, Q1 2023
Institutional positions in IO Biotech, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- 0 vs. Q4 2022
- Shares held
- 13.9M
- −363.7K (−2.5%) vs. Q4 2022
- Total value
- $26.1M
- −$6.77M (−20.6%) vs. Q4 2022
- New holders
- 2
- 2 more added
- Sold out
- 2
- 3 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IOBT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 12 | $199.0K |
| Q4 2025 | 22 | $4.78M |
| Q3 2025 | 21 | $3.59M |
| Q2 2025 | 26 | $25.3M |
| Q1 2025 | 22 | $20.8M |
| Q4 2024 | 27 | $18.2M |
| Q3 2024 | 20 | $24.8M |
| Q2 2024 | 20 | $30.7M |
| Q1 2024 | 18 | $47.4M |
| Q4 2023 | 18 | $55.3M |
| Q3 2023 | 19 | $41.7M |
| Q2 2023 | 15 | $24.0M |
| Q1 2023 | 17 | $26.1M |
| Q4 2022 | 17 | $32.8M |
| Q3 2022 | 21 | $41.6M |
| Q2 2022 | 18 | $72.2M |
| Q1 2022 | 19 | $76.9M |
| Q4 2021 | 20 | $92.6M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding IO Biotech, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ancora Advisors, LLC | 908 | $1.70K | 0.00% | 00.0% | Unchanged |
| Cannell Capital LLC | 12,594 | $23.6K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 12,730 | $23.8K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 19,917 | $37.0K | 0.00% | −637−3.1% | Reduced |
| Morgan Stanley | 43,195 | $81.0K | 0.00% | +14,135+48.6% | Added |
| Citadel Advisors LLC | 46,842 | $87.6K | 0.00% | +46,842 | New |
| Newtyn Management, LLC | 49,346 | $92.3K | 0.02% | −40,654−45.2% | Reduced |
| Renaissance Technologies LLC | 61,700 | $116.0K | 0.00% | +37,500+155.0% | Added |
| Bridgeway Capital Management, LLC | 132,200 | $247.2K | 0.01% | 00.0% | Unchanged |
| Capital World Investors | 418,499 | $782.6K | 0.00% | −652,812−60.9% | Reduced |
| PFM Health Sciences, LP | 507,640 | $951.8K | 0.04% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 1,008,437 | $1.89M | 0.39% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 1,400,000 | $2.63M | 0.01% | +1,400,000 | New |
| Bank of America Corp | 1,854,185 | $3.48M | 0.00% | 00.0% | Unchanged |
| Avoro Capital Advisors LLC | 2,055,883 | $3.84M | 0.06% | 00.0% | Unchanged |
| Vivo Capital, LLC | 3,015,545 | $5.65M | 0.42% | 00.0% | Unchanged |
| Novo Holdings A/S | 3,277,932 | $6.15M | 0.44% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 0 | $0 | 0.00% | −1,127,260−100.0% | Sold out |
| Psagot Value Holdings Ltd. / (Israel) | 0 | $0 | 0.00% | −40,846−100.0% | Sold out |